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Abstract: Since involved in synaptic transmission and located on X-chromosome, neuroligins 3 and
4X have been studied as good positional and functional candidate genes for autism spectrum disorder
pathogenesis, although contradictory results have been reported. Here, we performed a case-control
study to assess the association between noncoding genetic variants in NLGN3 and NLGN4X genes and
autism, in an Italian cohort of 202 autistic children analyzed by high-resolution melting. The results
were first compared with data from 379 European healthy controls (1000 Genomes Project) and then
with those from 1061 Italian controls genotyped by Illumina single nucleotide polymorphism (SNP)
array 1M-duo. Statistical evaluations were performed using Plink v1.07, with the Omnibus multiple
loci approach. According to both the European and the Italian control groups, a 6-marker haplotype
on NLGN4X (rs6638575(G), rs3810688(T), rs3810687(G), rs3810686(C), rs5916269(G), rs1882260(T))
was associated with autism (odd ratio = 3.58, p-value = 2.58 × 10−6 for the European controls; odds
ratio = 2.42, p-value = 6.33 × 10−3 for the Italian controls). Furthermore, several haplotype blocks
at 5-, 4-, 3-, and 2-, including the first 5, 4, 3, and 2 SNPs, respectively, showed a similar association
with autism. We provide evidence that noncoding polymorphisms on NLGN4X may be associated to
autism, suggesting the key role of NLGN4X in autism pathophysiology and in its male prevalence.
Keywords: autism; genetics; neuroligins; SNPs; haplotype analysis; noncoding regions
1. Introduction
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder with an early
onset, typically prior to age 3, characterized by impaired social interactions, absent or limited verbal
communication, and stereotyped and restricted pattern of interests [1]. Considering the great variability
of clinical presentations, the definition of ASD includes autism, Asperger’s syndrome, and pervasive
developmental disorder not otherwise specified (PDD-NOS) [2]. A combination of both genetic and
Int. J. Mol. Sci. 2016, 17, 1765; doi:10.3390/ijms17101765 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2016, 17, 1765 2 of 13
environmental causes, such as pesticides, heavy metals, dysbiosis, and mycotoxins, has been suggested
for ASD pathogenesis but, despite approximately 5%–15% of ASDs cases being due to identified genetic
or chromosomal alterations, the ASD etiology is still largely unknown [3–8]. Considering the higher
occurrence of ASD in males than in females, with a ratio of roughly 4:1, a role for the X-chromosome
in the ASD etiology has been also suggested [7,9]. In this regard, cytogenetic abnormalities highlight
the putative involvement of the loci from Xq12 to Xq21 and Xp22 in autism pathogenesis [10,11],
as well as associations with structural variants that have been reported for some X-chromosomal genes,
such as NLGN4X and MECP2 genes [12–15]. Since located on the X-chromosome and involved in
synaptic plasticity, both Neuroligin3 (NLGN3) and Neuroligin4X (NLGN4X), mapped at Xq13.1 and
Xp22.31, respectively, were extensively studied as good positional and functional candidates for ASD
predisposing. Neuroligins are postsynaptic cell-adhesion molecules that interact with the presynaptic
cell-surface receptors neurexins. Neurexins contain a single transmembrane domain, and together
with neuroligins they form Ca2+-dependent neurexin/neuroligin complexes. These transsynaptic
complexes play a crucial role in modulating neurotransmission and differentiation [16–18]. Several
ASD genetic studies have identified mutations affecting neuroligin proteins and influencing synaptic
function [19–21]. The involvement of neuroligins in ASD has been firstly confirmed in two Swedish
families by a de novo missense mutation (R451C) in NLGN3 and a frameshift mutation (1186insT) in
NLGN4X causing premature protein termination (D396X), respectively associated with typical autism
and Asperger’s syndrome [12]. Both these mutations resulted in an intracellular retention of the mutant
proteins, with a consistent loss of the synaptic activity, leading to neurodevelopmental defects and
mental retardation [22,23]. In mouse models, autism-associated NLGN3 mutations induced repetitive
behaviors, and R451C mutant mice showed impaired social interactions, but enhanced spatial learning
abilities [24–26]. A loss-of-function mechanism has also been suggested for the point mutation R87W
in NLGN4X, found in two brothers with classical ASD [27]. Recently, missense variations in NLGN3
(G426S) and NLGN4X (G84R, Q162K, and A283T) in Chinese ASD patients have been associated to
ASD predisposing, by causing abnormal synaptic homeostasis [28]. Deletion of exons 4, 5, and 6 in
NLGN4X have been also found in autistic children, suggesting that alternative splicing variants might
lead to abnormal neuroligin function in ASD [29,30]. Moreover, several noncoding genetic variants
have been specifically found in ASD patients [31–37]. All these variations often segregate into ASD
families [12,13] and can also be associated with different cognitive phenotypes, such as intellectual
and language disabilities [32,37], highlighting the role of neuroligins in the ASD pathogenesis. In
this regard, a de novo base pair substitution (−335G>A) in the promoter region of NLGN4X, has
been found in one autistic child with nonsyndromic mental retardation (NSMR) [32]. Since associated
with an increased level of NLGN4X transcripts, this variation probably affects the binding sites of
transcription factors in the mutated promoter sequence [32]. Four novel synonymous substitutions,
specific to ASD, have been reported in the coding sequences of the NLGN3 (p.K566K) and NLGN4X
(p.G99G; p.I172I; p.F530F) [34]. Despite the uncertainty of the physiological and clinical relevance,
they might affect the protein structures by altering splicing sites [34] or affecting gene regulation,
as they are located in conserved regulatory regions, such as enhancer- and promoter-associated
histone modification sites [33]. Moreover, a positive association with ASD has been identified in
a homogeneous autistic Chinese cohort (made of patients with typical phenotype), for a common
intronic variant in NLGN3 (rs4844285(G)) [6]. A three-marker haplotype (rs11795613(A), rs4844285(G),
rs4844286(T)), with a significant male bias, has been suggested, supporting the hypothesis that defects
of the synapse might have a role in ASD pathogenesis [6]. In addition, three haplotype sets in
NLGN4X (rs3810686(T), rs1882260(C)), (rs6638575(G), rs3810686(T), rs18882260(T)) and (rs6638575(A),
rs3810686(C), rs18882260(C)), have been positively associated with nonspecific mental retardation
(Intelligence Quotients IQs < 70) and social disability scores ≤ 8 [36] and genetic variants in NLGN4X
also have a significant effect on male cognitive abilities, highlighting the role of neuroligins in
psychiatric conditions [37].
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However, contradictory results have been also provided in validating the relevance and frequency
of neuroligin genetic variants in ASD [38–41]. Wermenter and coworkers failed to find an involvement
of NLGN3 and NLGN4X with ASD in a study group of 107 probands with autistic disorders at a
high-functioning level [40], and similar results have been reported in the Quebec population, after
screening for neuroligin mutations in 96 individuals diagnosed with ASD [41]. Lastly, no association
was found between NLGN3/NLGN4X alterations and ASD in a Chinese cohort [38]. However, the
genetic heterogeneity of ASD, as well as differences in the ethnicity background of ASD samples, make
it difficult to elucidate the involvement of neuroligin genes in autism pathogenesis.
Considering all these evidences and starting from an Italian ASD sample set, we assessed the
effects of three noncoding genetic variants in NLGN3, already reported as associated with ASD in
a Chinese cohort [6], and six common single nucleotide polymorphisms (SNPs) in NLGN4X, only
partially described in literature [36], with the final aim to validate the selected genetic variants as
susceptibility loci for ASD.
2. Results
2.1. Single-Locus Analysis
Association analyses have been performed considering SNPs located in the intronic and 3′ UTR
regions of NLGN3 and NLGN4X, considering both the European (EUR) population (1000 Genomes
Project, Phase 2) [42] and the Italian population. Genotype counts of SNPs and results of the
Hardy–Weinberg statistics, which do not present any significant disequilibrium, are shown in Tables
S1 and S2. As shown in Table 1, a moderate statistical significance difference (odds ratio (OR) = 1.453,
p = 0.0456) was identified in the single-locus analysis only for SNP rs3810688, with the minor allele T
having frequency slightly lower in ASD cases in comparison to EUR controls (separate results for male
and female analysis are provided in Tables S3 and S4). However, this association lost its significance
after False Discovery Rate (FDR) correction for multiple testing (Table 1). As the number of samples
was quite limited, Fisher’s exact test has been chosen for comparing SNP allelic frequencies between
cases and unrelated controls, always using the genetic data from the 1000 Genomes Project (Phase 2)
as reference population [42]. We also verified that the allelic frequencies for all the SNPs analyzed
do not statistically deviate in our control data set from those reported in the 1000 Genomes Project
EUR population. The moderate statistical association of rs3810688(T) with autism disappeared when
comparing ASD data with those from Italian controls.
Table 1. Single locus analysis for all the single nucleotide polymorphisms (SNPs) genotyped in NLGN3
and NLGN4X (EUR control population).
Gene ID SNP ID MinorAllele
MAF
Controls
MAF
Case p-Value OR 95% CI p-Corr
NLGN3
rs11795613 G 0.481 0.515 0.398 1.144 0.816–1.617 0.701
rs4844285 A 0.4741 0.4895 0.701 1.064 0.755–1.496 0.701
rs4844286 T 0.505 0.481 0.5396 0.908 0.646–1.280 0.701
NLGN4X
rs6638575 A 0.266 0.301 0.303 1.193 0.856–1.663 0.404
rs3810688 T 0.2176 0.288 0.0456 1.453 1.018–2.074 0.152
rs3810687 T 0.1086 0.1339 0.3369 1.269 0.805–2.000 0.404
rs3810686 T 0.4466 0.4561 0.817 1.039 0.768–1.407 0.817
rs5916269 A 0.1086 0.1339 0.3369 1.269 0.805–2.000 0.404
rs1882260 C 0.2655 0.3347 0.0505 1.392 1.005–1.928 0.152
Statistical significance, for the single locus association analysis, was tested at p < 0.05, after Fisher’s exact
test. The p-values have been adjusted by false discovery rate (FDR) correction for multiple test analysis. MAF
controls, frequency of the minor allele in controls (n = 379); MAF case, frequency of the minor allele in case
(n = 202); OR, odds ratio; CI, confidence interval; p-corr, corrected p-value after FDR test.
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2.2. Haplotype Analysis (EUR Control Population)
A 6-SNPs haplotype block in NLGN4X showed a strong significant association with ASD cases
(odds ratio = 3.58, p-value = 2.58 × 10−6), also after logistic regression and 100,000 permutation tests
(empirical p-value < 1 × 10−5, empirical q-value < 1 × 10−5) (Table 2). This block (rs6638575(G),
rs3810688(T), rs3810687(G), rs3810686(C), rs5916269(G), rs188260(T)) includes the SNP rs3810688(T),
moderately associated with ASD in the single-locus analysis. Indeed, haplotypes on NLGN4X
have been also analyzed as 5-, 4-, 3-, or 2-loci blocks, as reported in Table 2. A good statistical
significance was obtained with blocks including the SNP rs3810688(T), especially together with
the haplotype sets also including the SNPs rs3810687(G) and rs3810686(C)—both located in the 3′
UTR of NLGN4X—and with rs6638575(G), in the intron 5 of NLGN4X (Table 2). These variants
are part of two 5-loci (rs6638575(G), rs3810688(T), rs3810687(G), rs381086(C), rs5916269(G)) and
(rs3810688(T), rs3810687(G), rs381086(C), rs5916269(G), rs1882260(T)), two 4-loci (rs6638575(G),
rs3810688(T), rs3810687(G), rs381086(C)) and (rs3810688(T), rs3810687(G), rs3810686(C), rs5916269(G)),
two 3-loci (rs6638575(G), rs3810688(T), rs3810687(G)) and (rs3810688(T), rs3810687(G), rs3810686(C))
and two 2-loci (rs6638575(G), rs3810688(T)) and (rs3810688(T), rs3810687(G)) combinations, all with
strong statistical association with ASD. Moreover, despite the single-locus analysis not showing any
statistical difference for the SNPs rs1882260 and rs5916269, haplotype analysis showed that two
2-blocks (rs5916269(G), rs1882260(T)) and (rs3810686(C), rs5916269(G)), two 3-blocks (rs3810686(C),
rs5916269(G), rs1882260(T)) and (rs3810687(G), rs3810686(C), rs5916269(G)) and one 4-block loci
(rs3810687(G), rs3810686(C), rs5916269(G), rs1882260(T)), respectively, have also a very strong
significant association with ASD (Table 2). Similar results have been obtained also comparing the
ASD haplotype frequencies of NLGN4X with our unrelated controls, suggesting the reliability of the
selected control population for the statistical analysis (EUR Phase 2, 1000 Genomes Project).
Table 2. Haplotype association analysis in NLGN4X (EUR control population).
N SNPs in Haplotypes ControlFrequency
Case
Frequency Haplotype p-Value
Emp.
p-Value
Emp.
q-Value
6 rs6638575-rs3810688-rs3810687-rs3810686-rs5916269-rs1882260 0.0335 0.1799 GTGCGT 2.58 × 10
−6 <1 × 10−5 <1 × 10−5
5 rs6638575-rs3810688-rs3810687-rs3810686-rs5916269 0.0805 0.1799 GTGCG 7.60 × 10
−6 <1 × 10−5 <1 × 10−5
5 rs3810688-rs3810687-rs3810686-rs5916269-rs1882260 0.0335 0.1799 TGCGT 2.58 × 10
−6 <1 × 10−5 <1 × 10−5
4 rs6638575-rs3810688-rs3810687-rs3810686 0.0805 0.1799 GTGC 7.6 × 10
−6 <1 × 10−5 2 × 10−5
4 rs3810688-rs3810687-rs3810686-rs5916269 0.0801 0.1793 TGCG 7.6 × 10
−6 <1 × 10−5 2 × 10−5
4 rs3810687-rs3810686-rs5916269-rs1882260 0.0943 0.1793 GCGT 1.3 × 10
−5 <1 × 10−5 2 × 10−5
3 rs6638575-rs3810688-rs3810687 0.3538 0.4463 GTG 8.16 × 10−6 <1 × 10−5 <1 × 10−5
3 rs3810688-rs3810687-rs3810686 0.0701 0.1793 TGC 7.6 × 10−6 <1 × 10−5 <1 × 10−5
3 rs3810687-rs3810686-rs5916269 0.4062 0.4445 GCG 8.16 × 10−4 6.99 × 10−4 3.2 × 10−3
3 rs3810686-rs5916269-rs1882260 0.0943 0.1793 CGT 1.3 × 10−5 <1 × 10−5 3 × 10−4
2 rs6638575-rs3810688 0.2109 0.2854 GT 1.08 × 10−4 7 × 10−5 8.3 × 10−4
2 rs3810688-rs3810687 0.0943 0.1793 TG 1.3 × 10−5 2 × 10−5 1.5 × 10−4
2 rs3810687-rs3810686 0.4062 0.4445 GC 8.16 × 10−4 7.3 × 10−4 5 × 10−3
2 rs3810686-rs5916269 0.4062 0.4445 CG 8.16 × 10−4 7.3 × 10−4 5 × 10−3
2 rs5916269-rs1882260 0.4314 0.6259 GT 2.4 × 10−8 <1 × 10−5 <1 × 10−5
Haplotype combinations with significant p-values (p < 0.05), using the EUR control population, after permutation
test, have been reported for all the SNPs located on NLGN4X. Empirical p-values and empirical q-values after
100,000 permutations are reported. Only haplotypes having case frequency >0.05 have been presented.
No statistically significant haplotypes have been found in the NLGN3 after logistic regression and
permutation analysis.
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2.3. Haplotype Analysis (ITA control Population)
The analysis was then repeated comparing the frequencies of NLGN4X SNPs between ASD
cases and 1061 healthy controls collected during the Hypergenes project [43]. The association with
the 6-marker haplotype remained, although weaker than the EUR population (odds ratio = 2.42,
p-value = 6.33 × 10−3, empirical p-value = 6.79 × 10−3, empirical q-value < 2.73 × 10−2). A weaker
association was also found for most of the 5-, 4-, 3- and 2-SNP haplotypes identified considering the
EUR population. Data are reported in Table 3.
Table 3. Haplotype association analysis in NLGN4X (ITA control population).
N SNPs in Haplotypes ControlFrequency
Case
Frequency Haplotype p-Value
Empirical
p-Value
Empirical
q-Value
6 rs6638575-rs3810688-rs3810687-rs3810686-rs5916269-rs1882260 0.0678 0.1799 GTGCGT 6.33 × 10
−3 6.79 × 10−3 2.73 × 10−3
5 rs6638575-rs3810688-rs3810687-rs3810686-rs5916269 0.1349 0.1799 GTGCG 1.9 × 10
−2 1.87 × 10−2 4.47 × 10−2
5 rs3810688-rs3810687-rs3810686-rs5916269-rs1882260 0.0678 0.1799 TGCGT 6.33 × 10
−3 5.39 × 10−3 2.78 × 10−2
4 rs6638575-rs3810688-rs3810687-rs3810686 0.1189 0.1799 GTGC 1.66 × 10
−2 1.62 × 10−2 4.41 × 10−2
3 rs6638575-rs3810688-rs3810687 0.3782 0.4463 GTG 1.56 × 10−2 1.29 × 10−2 4.37 × 10−2
3 rs3810688-rs3810687-rs3810686 0.0801 0.1793 TGC 1.17 × 10−2 1.26 × 10−2 4.78 × 10−2
3 rs3810687-rs3810686-rs5916269 0.3360 0.4445 GCG 3.99 × 10−3 4.10 × 10−3 1.98 × 10−2
2 rs3810687-rs3810686 0.3160 0.4445 GC 3.50 × 10−3 3.20 × 10−3 2.20 × 10−2
2 rs3810686-rs5916269 0.3360 0.4445 CG 3.99 × 10−3 3.70 × 10−3 2.53 × 10−2
Haplotype combinations with significant p-values (p < 0.05), using the ITA control population, after permutation
test, have been reported for all the SNPs located on NLGN4X. Empirical p-values and empirical q-values after
100,000 permutations are reported. Only haplotypes having case frequency >0.05 have been presented.
2.4. Linkage Disequilibrium Analysis
The results for linkage disequilibrium (LD) analysis for the considered SNPs in NLGN4X are
presented in Figure 1. Panel (a) represents the LD for SNPs in the EUR control populations; panel (b)
shows the LD scores for the ITA control population patients; panel (c) reports the results achieved for
ASD patients.
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Figure 1. Linkage disequilibrium (LD) for the SNPs analyzed in NLGN4X calculated using Haploview:
in panel (a) for the EUR population (1000 Genomes Project, Phase 2); in panel (b) for the Italian control
population; and in panel (c) for the autistic patients enrolled in our study.
3. Discussion
According to our results, common noncoding variants in NLGN4X may play a role in ASD
susceptibility. Starting from a relatively homogenous sample and a case-control study design, our
results suggest that some SNP marker haplotype blocks, located in the 3′ UTR of NLGN4X, might be
associated to ASD. After a first statistical analysis, referring to EUR 1000 Genomes Project population
as control, the 3′ UTR of NLGN3 did not show any association with ASD, nor at single SNP or at
haplotype blocks. On the other hand, the 3′ UTR of NLGN4X displayed statistical association with the
disease at single SNP rs3810688(T), which is the minor allele (Table 1), although this significance was
lost after FDR correction. Indeed, although the frequency of this allele is higher in the ASD population
in comparison to EUR and ITA controls, the allele is still present in 21% of EUR population, thus
producing only a modest effect by itself.
To confirm the statistical association of the haplotype blocks with ASD, (Table 2), we repeated the
same statistical analyses, referring to the ITA healthy population, and confirmed the association,
although weaker, between some SNP marker haplotypes in the 3′ UTR of NLGN4X and ASD.
Indeed, the haplotype analysis revealed a 6-SNPs haplotype block (rs6638575(G), −rs3810688(T),
−rs3810687(G), −rs3810686(C), −rs5916269(G), −rs1882260(T)) with a significant association with
ASD, even after correction by permutation both referring to EUR (Table 2) and ITA control cohort
populations (Table 3). In particular, in the region spanning from SNPs rs6638575 to rs3810686, several
multiloci haplotype blocks were found to be associated with ASD (Tables 2 and 3). Within the haplotype
Int. J. Mol. Sci. 2016, 17, 1765 7 of 13
blocks containing rs3810687 and rs3810686, both SNPs always displayed the G allele. Interestingly,
considering the LD analysis, we notice that the considered SNPs on NLGN4X are more in linkage than
in control populations (Figure 1).
These results might imply that an approximately 4 kb region in the 3′ UTR of NLGN4X, spanning
from SNPs rs66385775 to rs1882260, could be involved in autism susceptibility. This regulatory region
in NLGN4X might have a role in modulating neuroligin biological function and, therefore, in causing or
predisposing to neurological disorders. Since NLGN4X is involved in synaptic plasticity and X-linked,
it might be a key gene in ASD pathogenesis and in its sex bias.
On the other hand, no associations were found for variants located on NLGN3 at the single
locus and haplotype analysis, despite Yu and coworkers (2011) reporting a positive association for
the variants rs11795613(A), rs4844285(G), and rs4844286(T) with ASD [6]. Differences in sample
ethnicity and size, as well as the ASD heterogeneity, might be taken into account for explaining such
different results. Further studies, performed on a greater number of patients and with different genetic
backgrounds, will be required to elucidate the role of NLGN3 in autism susceptibility.
Nonetheless, our results are partially in agreement with Qi and collaborators (2009) that reported
a positive association between SNPs in NLGN4X (rs6638575, rs3810686, rs1882260) and NSMR in
a Chinese population [36]. In this regard, four putative haplotype combinations (rs3810686(T),
rs1882260(T)), (rs3810686(C), −rs1882260(C)) and (rs6638575(G), rs3810686(T), rs18882260(T)) and
(rs6638575(A), rs3810686(C), rs18882260(C)), in the sixth exon of NLGN4X have been reported as
positively associated to NSMR in this Chinese cohort [36]. This genomic region, in fact, plays a
crucial role for the biological function of NLGN4X, encoding for the transmembrane domain and
postsynaptic density 95-disc large zone occludens-1 binding domain, both necessary for N-methyl
aspartate receptors and downstream signal-transducing proteins. Furthermore, it has been reported
that a target haplotype composed of the SNPs rs5916271(C) and rs6638575(A) had a significant effect in
improving the general cognitive ability and especially verbal comprehension in male children, although
further studies are required to highlight the role of these polymorphisms in ASD susceptibility [37].
As none of the analyzed SNPs on NLGN4X produce amino acid changes, two possible explanations
should be taken into account for their association with ASD. First, considering the regulatory role of the
3′ UTR regions in modulating gene expression, the SNPs located in this region, correlated with ASD,
might affect miRNA-binding sites, leading to impairments in NLGN4X expression. In this regard, the
SNPs analyzed in this study might be located in or very close to putative miRNA regulatory regions,
breaking or creating miRNA-binding sites with a possible effect on NLGN4X expression and thus on
synaptic transmission. To this respect, it has been reported that a single nucleotide variant located in
the 5′ UTR of NLGN4X is able to affect neuroligin expression [32], but further studies are required
to validate if such a regulatory mechanism might also occur for the genetic variants in the 3′ UTR of
neuroligin genes. Second, it might be also possible that other genetic variants, as putative predisposing
loci or causative mutations, could exist in close linkage with the SNPs analyzed on NLGN4X, leading
to differences in NLGN4X expression through alternative splicing or amino acid variations since each
of these conditions can alter the biological function of NLGN4X.
Considering that males have higher predisposition in ASD etiology, an involvement of the
X-chromosome in autism susceptibility has been suggested by genetic and cytogenetic studies [9–13]
and several putative candidate genes, including neuroligins, have been largely investigated [7,8,23–37].
Nonetheless, taking advantages of the new sequencing technologies, further insights might be provided
in discovering new X-linked genetic variants associated with ASD predisposition or its etiology.
Although the sample size of patients is quite limited for a genetic association study, statistical
association between marker haplotype blocks located at 3′ UTR of NLGN4X and ASD was found
referring both to EUR and ITA populations. Indeed, despite the stronger statistical significance found
in reference to EUR controls, similar results were obtained in reference to ITA controls.
After all, considering the heterogeneity of ASD, in terms of symptoms, severity, and comorbidities,
it sounds reasonable that several genes might be involved in ASD predisposition, as well as epigenetics
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or environmental factors. For this reason, a single genetic variant or haplotype, even if in a regulatory
region or in a candidate gene, seems unlikely to be playing a major role in ASD predisposition. Thus,
further functional and genetic studies coupled to these SNP profiles in a larger ASD cohort would be
the next steps to elucidate the role of neuroligins and genetic variants in ASD etiology. Indeed, these
SNPs could be the markers of other genetic variations or associated to specific phenotypes. Moreover,
as gene–environment interaction has also been proposed for autism pathogenesis, further studies
considering both the genetic and environmental risk factors should be designed.
As for clinical application, the relation between these genetic risk factors and symptoms or ASD
characteristics could suggest molecular and epigenetic mechanisms triggering the disease and suggest
possible preventive or therapeutic intervention.
In our study we found and discussed the association of several noncoding genetic variants in the
NLGN4X gene with ASD in an Italian cohort. This implies that neuroligins and, therefore, impairments
at the synaptic transmission, might play a role in ASD susceptibility and pathophysiology. To date, no
other works have investigated the role of neuroligin noncoding variants in ASD susceptibility in an
Italian autistic population, although Blasi and coworkers (2006) failed to find a significant association
with ASD in neuroligin coding variants [39] when analyzing Italian ASD patients. Taking into account
the contradictory results in validating the role of neuroligins in ASD predisposition as well as the
complex etiology of this disease, our findings can be important for the characterization of this disease,
although they need to be confirmed and replicated in different ethnic groups and to be associated with
phenotypic and epigenetic data.
4. Materials and Methods
4.1. Subjects
The sample-sets consist of: 202 ASD patients (165 (81.7%) males; 37 (18.3%) females), recruited by
IRCCS Eugenio Medea-La Nostra Famiglia in two different and far areas of Italy: Bosisio Parini (Lecco,
Italy) in the North and Ostuni (BR, Italy) in the South. Patients had an age ranging between 2 and
12 years. Demographic characteristics are summarized in Table 4.
Table 4. Demographic data and diagnosis of autistic patients.
Patients: 202; Age: 2–12; Males: 165; Females: 37
Patients from North Italy: n = 157
Males: 131, 83.44%
Young autism: 93 (71%)
PDD-NOS: 34 (26%)
Asperger’s Syndrome: 4 (3%)
Females: 26, 16.56%
Young autism: 18 (69.2%)
PDD-NOS: 7 (27%)
Asperger’s Syndrome: 1 (3.8%)
Patients from South Italy: n = 45
Males: 34, 75.55%
Young autism: 24 (70.6%)
PDD-NOS: 9 (26.5%)
Asperger’s Syndrome: 1 (2.9%)
Females: 11, 24.45%
Young autism: 8 (72.7%)
PDD-NOS: 3 (27.3%)
Asperger’s Syndrome: 0
The diagnosis for young autism (70.3%), Asperger’s syndrome (3.5%), or PDD-NOS (26.2%) were
performed according to DSM-IV TR (APA, 2000) and by the Autism Diagnostic Observation Scale
(ADOS) and ADI-R. IQ, cognitive tests, and behavioral analyses were also done in all the patients,
but 20, and are summarized in Table 5. Patients with genetic syndromes, epilepsy, and
neuroradiological confirmed disorders were excluded.
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Table 5. Cognitive and behavioral characteristics of autistic patients.
IQ Hyperactivity Language and Communication
>70 n = 71 (35.1%) Level 1: IQ > 101; n = 15 (7.4%) Level 0: n = 136; (67.3%) Level 1: n = 7 (3.5%)Level 2: 100 > IQ> 70; n = 56 (27.7%) Level 2: n = 48 (23.7%)
≤69 n = 131 (64.6%)
Level 3: 69 > IQ > 50; n = 79 (39.1%) Level 1: n = 53 (26.2%) Level 3: n = 65 (32.2%)Level 4: 49 > IQ > 35; n = 28 (13.9%) Level 4: n = 64 (31.7%)
Level 5: 34 > IQ> 20; n = 17 (8.4%) Level 2: n = 13 (6.5%) Level 5: n = 3 (1.5%)Level 6: IQ < 19; n = 7 (3.5%) 15 patients not evaluated (7.4%)
One thousand sixty one healthy controls, collected during the Hypergenes Project [43] (European
Network for Genetic-Epidemiological Studies; www.hypergenes.eu) were included in the study. These
controls were from the same two areas of Italy from which patients were recruited and in similar
proportion. The healthy subjects were genotyped at the University of Milan, using the Illumina
1M-duo array (San Diego, CA, USA) and imputed with Minimac software [44], a low-memory, fast,
flexible, computationally efficient implementation of the Markov chain haplotyping method, using the
haplotypes from the 1000 Genomes Project (March 2012) as reference [42].
The data relative to the SNPs considered in the statistical analyses were obtained directly from
genotyping for rs5916269, rs3810686, rs3810687, and rs663857 and by imputation for rs1882260
and rs3810688.
The Ethical committees of IRCCS Eugenio Medea-La Nostra Famiglia and of Hypergenes project
approved the study.
Moreover, genotype data from the 1000 Genomes Project (Phase 2) [42] were also used as control
cases, considering the 379 individuals with EUR genotype.
4.2. Selection of SNPs
The NCBI Accession Numbers, used as reference sequences for NLGN3 and NLGN4X were,
respectively, NG_015874 and NG_008881. Relying on literature [6,36], a selection of SNPs located in
the intronic or 3′ UTR regions of both NLGN3 and NLGN4X were genotyped. Furthermore, three
additional SNPs, located in the 3′ UTR of NLGN4X, have been included since they are located in a
putative regulatory region and have a close map distance with the previously selected SNPs. In this
regard, the inter-SNP distance, for the SNPs analyzed in NLGN3 and NLGN4X, was less than 5 kb.
All the studied SNPs have a minor allele frequency (MAF) >0.05—as reported by the 1000 Genomes
Project (Phase 2) in the EUR population—and are listed in the Table 6. Linkage disequilibrium for
SNPs considered in this study has been calculated using Haploview [45], and the most relevant LD
scores for these data are displayed in Figure 1. Figure S1 represents the LD scores (derived from the
1000 Genomes Project EUR population) of all the SNPs located in NLGN4X, including those selected
for our analyses and the related TAG SNPs.
Table 6. List of SNPs analyzed in NLGN3 and NLGN4X.
Genes SNPs Alleles MAF Position in Gene References
NLGN3
rs11795613 (A/G) G: 0.49 Intron 1
Yu et al., Behav. Brain Funct. 2011, 7, 13 [6]rs4844285 (A/G) A: 0.48 Intron 2
rs4844286 (T/G) T: 0.49 Intron 2
NLGN4X
rs6638575 (A/G) A: 0.28 Intron 5
Qi et al., Psychiatr. Genet. 2009, 19, 1 [36]rs3810686 (T/C) T: 0.44 3′ UTR
rs1882260 (C/T) C: 0.27 3′ UTR
rs3810687 (T/G) T: 0.11 3′ UTR
–rs3810688 (T/C) T: 0.29 3′ UTR
rs5916269 (A/G) A: 0.11 3′ UTR
All the SNPs analyzed as well as their position along the NLGN3 and NLGN4X genes and MAF, are listed. MAF
is referred to that reported for the EUR population (1000 Genomes Project, Phase 2). According to literature, their
association to autism or psychiatric conditions, has been also reported. SNP: Single Nucleotide Polymorphism;
MAF: Minor Allele Frequency; UTR: Untranslated Region.
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4.3. SNPs Screening and Genotyping
Genomic DNA was extracted from peripheral blood samples, using commercial kit
(Macherey-Nagel GmbH & Co. KG, Düren, Germany). SNPs located on both NLGN3 and NLGN4X
were amplified and genotyped by high-resolution melting analysis (HRM) (Rotor-Gene® Q-Pure
detection, Qiagen, Venlo, The Netherlands). For each sample a total of 20 ng of genomic DNA
was amplified in a 20 µL reaction mixture Phusion Flash High Fidelity PCR Master Mix (Thermo
Fisher Scientific, Waltham, MA, USA), Stati Uniti of primer mix (0.7 each) and 5% of the intercalating
dye EvaGreen (Biotium Inc., Fremont, CA, USA), with 1.4, as final concentration. HRM analysis
primers were designed by PRIMER3plus software (http://bioinfo.ut.ee/primer3-0.4.0/primer3/).
All samples were analyzed in duplicates, and for each selected SNP three internal controls—resembling
all three possible genotypes, previously characterized by Sanger-sequencing—have been included. The
temperature raising for the HRM analysis was of 0.1 ◦C/s. Normalized melting curves and differential
graphs have been compared for the genotype analysis. Primers and amplification details are shown in
the Table S5.
4.4. Statistical Analysis
A first screening was performed comparing the data obtained from ASD patients with those
from the European subset of the 1000 Genomes Project (EUR Phase 2 population). SNP association
analyses were performed first using Plink v1.07 [46] to test for possible associations between all the
SNPs identified in NLGN3 and NLGN4X and ASD. The two-tailed Fisher’s exact test was chosen
to compare the polymorphisms’ distributions (cases vs. controls) and testing their significance at
p < 0.05, under the null hypothesis of no association between each SNP and ASD. The p-values have
been adjusted by false discovery rate (FDR) correction for multiple test analysis.
Using the same control data, haplotype tests were also performed using Plink v1.07. Omnibus
multiple loci analyses were carried out for all the SNPs included in this study regarding NLGN3 and
NLGN4X, using logistic regression under the null hypothesis of no association between haplotypes
and ASD. Permutation tests (100,000 permutations) were used to correct the p-values. Haplotypes with
p-values equal or below the α threshold of 0.05 were considered as statistically significant.
The same statistical analyses were performed on SNPs in NLGN4X, which revealed a significant
correlation with ASD, considering two groups of Italian healthy controls recruited in the same two
areas of Italy in which patients were recruited.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/17/10/1765/s1.
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Abbreviations
ASD Autism spectrum disorder
EUR European
FDR False discovery rate
HRM High resolution melting
IQ Intelligence Quotient
ITA Italian
MAF Minor allele frequency
NLGN Neuroligin
NSMR Non-syndromic mental retardation
PDD-NOS Pervasive developmental disorder-not otherwise specified
SNP Single nucleotide polymorphism
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